Amgen maps a PhIII journey for its latest great cardio drug hopeful. Can it succeed this time?
Just a few days ago, Amgen CEO Bob Bradway touted one of the company’s cardio programs for a drug called olpasiran as one of the top drugs in the pipeline. And now Bradway’s pharma giant has taken the wraps off a detailed and updated outline of Phase II data as it explains its hopes for a major new therapy in the sector.
The siRNA drug — originally pushed into the spotlight on the setback of Amgen’s partnered drug omecamtiv a couple of years ago — essentially wiped out all but small amounts of lipoprotein(a) (Lp(a) levels in patients suffering from atherosclerotic cardiovascular disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
